RCMNY
DTIL icon

Rubric Capital Management (New York)’s Precision BioSciences DTIL Stock Holding History

Rubric Capital Management (New York)’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-88,571
Closed -$3.16M – 78
2022
Q4 		$3.16M Hold
88,571
– – 0.14% 81
2022
Q3 		$3.45M Hold
88,571
– – 0.17% 73
2022
Q2 		$4.25M Buy
+88,571
New +$5.2M 0.22% 66

Other funds holding DTIL

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rubric Capital Management (New York)'s DTIL Position: Q1 2023 in Review

Rubric Capital Management (New York) sold out of Precision BioSciences (DTIL) in Q1 2023, closing a stake of 88,571 shares — an estimated $3.16M sold.

Rubric Capital Management (New York) first reported a position in DTIL in Q2 2022 and held it in 3 quarters. The position peaked at $4.25M in Q2 2022. 86 funds tracked by Wall St. Rank hold DTIL as of Q1 2023.

  • Rubric Capital Management (New York) reported no remaining Precision BioSciences position as of Q1 2023 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 88,571 Precision BioSciences shares in Q1 2023, an estimated $3.16M.
  • Rubric Capital Management (New York) first reported a position in Precision BioSciences in Q2 2022 and held it in 3 quarters.
  • Rubric Capital Management (New York)'s Precision BioSciences position peaked at $4.25M in Q2 2022.
  • 86 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2023, filed 12 May 2023.